Market Assessment
Enanta (ENTA) is a commercial-stage small market cap ($1.8B) biopharma that has established itself as an innovator of effective therapeutics for the viral liver disease, HCV infection, through the approval of paritaprevir and glecaprevir. Its license agreement with AbbVie (ABBV) for the HCV therapeutics, paritaprevir and glecaprevir, is providing royalty revenues, which is aiding in the creation of novel drug assets for liver diseases.
The most well recognized FXR agonist, Obeticholic acid (OCA) by Intercept (ICPT) announced in Q1/2019 that the Phase 3 REGENERATE study of